Barclays Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective upped by Barclays from $150.00 to $165.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Barclays‘s price target indicates a potential upside of 13.71% from the company’s current price.

A number of other equities research analysts have also recently weighed in on PODD. Royal Bank Of Canada lifted their price target on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday. Robert W. Baird set a $175.00 price objective on Insulet in a report on Thursday, August 6th. Truist Financial cut Insulet from a “buy” rating to a “hold” rating and lowered their target price for the company from $210.00 to $153.00 in a research report on Wednesday, August 5th. Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Finally, Benchmark reduced their price target on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $192.96.

Insulet Stock Performance

NASDAQ:PODD traded down $11.02 during mid-day trading on Friday, hitting $145.10. The stock had a trading volume of 385,956 shares, compared to its average volume of 1,392,775. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 1.25 and a beta of 1.06. The company has a 50 day simple moving average of $141.91 and a 200-day simple moving average of $177.34. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. During the same period in the previous year, the business posted $1.24 EPS. Insulet’s revenue was up 19.2% on a year-over-year basis. On average, research analysts expect that Insulet will post 6.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Insulet in the 2nd quarter valued at $1,018,582,000. Arrowstreet Capital Limited Partnership raised its holdings in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc acquired a new stake in Insulet during the 2nd quarter worth about $78,746,000. Amundi raised its holdings in Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock worth $77,320,000 after buying an additional 60,929 shares during the period. Finally, Bank of America Corp DE purchased a new stake in Insulet during the second quarter valued at about $64,921,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Third-quarter performance was strong: Insulet reported $842 million in revenue, up 19.2% year over year, and adjusted EPS of $1.99, beating analyst estimates. The company also announced a $1 billion share repurchase program. Insulet CEO discusses growth and competition
• Positive Sentiment: Several firms lifted their price targets. RBC raised its target to $180 and kept an Outperform rating; Bernstein raised its target to $200 and also rated the shares Outperform. RBC raises Insulet price target
• Neutral Sentiment: Other target increases came with Neutral or Market Perform ratings, suggesting analysts see potential recovery but remain measured in their outlook. RBC also described the valuation as attractive while noting a more conservative 2027 outlook. RBC on Insulet valuation and outlook
• Negative Sentiment: The main concern is slower growth expected in 2027. Insulet’s CEO also expects competitors to take some Omnipod market share, raising questions about the pace of future growth despite the latest-quarter beat. Insulet CEO discusses growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.